# Filing Detail

Form PRE 14A - Other preliminary proxy statements:
SEC Accession No. 0001104659-24-101004
Filing Date
2024-09-18
Accepted
2024-09-18 17:06:44
Documents
5
Period of Report
2024-09-18

Document Format Files

Seq | Description | Document | Type | Size
--- | --- | --- | --- | ---
1 | PRE 14A | tm2424296d1_pre14a.htm | PRE 14A | 490749
2 | GRAPHIC | tm2424296d1_pre14asp01img01.jpg | GRAPHIC | 2945
3 | GRAPHIC | tm2424296d1_pre14aimg001.jpg | GRAPHIC | 147510
4 | GRAPHIC | tm2424296d1_pre14aimg002.jpg | GRAPHIC | 140076
5 | GRAPHIC | tm2424296d1_pre14asp01img02.jpg | GRAPHIC | 473266
| Complete submission text file | 0001104659-24-101004.txt |  | 1544168

Mailing Address 9605 MEDICAL CENTER DRIVE SUITE 270 ROCKVILLE MD 20850
Business Address 9605 MEDICAL CENTER DRIVE SUITE 270 ROCKVILLE MD 20850 (734) 332-7800
Theriva Biologics, Inc. (Filer) CIK: 0000894158 (see all company filings)

EIN.: 133808303 | State of Incorp.: NV | Fiscal Year End: 1231
Type: PRE 14A | Act: 34 | File No.: 001-12584 | Film No.: 241308247
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)